Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran Duration After Catheter Ablation for Paroxysmal AF
NCT02313584Phase 3Unknown
- Sponsor
- Korea University
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in thromboembolism (2 arms), sponsored by Korea University. Primary endpoint: Rate of thromboembolic events at 2 months. Status: unknown.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02313584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313584.